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Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by a
multi-systemic vascular dysplasia and hemorrhage. The precise factors leading to these
vascular malformations are not yet understood and robust animal models of HHT are
essential to gain a detailed understanding of the molecular and cellular events that lead
to clinical symptoms, as well as to test new therapeutic modalities. Most cases of
HHT are caused by mutations in either endoglin (ENG) or activin receptor-like kinase 1
(ACVRL1, also known as ALK1). Both genes are associated with TGFβ/BMP signaling,
and loss of function mutations in the co-receptor ENG are causal in HHT1, while HHT2
is associated with mutations in the signaling receptor ACVRL1. Significant advances in
mouse genetics have provided powerful ways to study the function of Eng and Acvrl1 in
vivo, and to generate mouse models of HHT disease. Mice that are null for either Acvrl1
or Eng genes show embryonic lethality due to major defects in angiogenesis and heart
development. However mice that are heterozygous for mutations in either of these genes
develop to adulthood with no effect on survival. Although these heterozygous mice exhibit
selected vascular phenotypes relevant to the clinical pathology of HHT, the phenotypes
are variable and generally quite mild. An alternative approach using conditional knockout
mice allows us to study the effects of specific inactivation of either Eng or Acvrl1 at
different times in development and in different cell types. These conditional knockout
mice provide robust and reproducible models of arteriovenous malformations, and they
are currently being used to unravel the causal factors in HHT pathologies. In this review,
we will summarize the strengths and limitations of current mouse models of HHT, discuss
how knowledge obtained from these studies has already informed clinical care and explore
the potential of these models for developing improved treatments for HHT patients in the
future.
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INTRODUCTION TO HHT AND IMPORTANCE OF MOUSE
MODELS
Hereditary hemorrhagic telangiectasia (HHT) is inherited as an
autosomal dominant disease and has a prevalence of approxi-
mately one case per 5000–8000 individuals (Bideau et al., 1989;
Kjeldsen et al., 1999; Dakeishi et al., 2002). Mutations in endoglin
(ENG) are responsible for HHT1 (McAllister et al., 1994), while
mutations in activin receptor-like kinase (ACVRL1 also known
as ALK1) are responsible for HHT2 (Johnson et al., 1996).
A rare form of HHT disease in which vascular lesions are com-
bined with juvenile polyposis is due to mutations in SMAD4
(Gallione et al., 2004). Whole genome sequencing will ultimately
map the genetic cause of HHT in patients where mutations
have not yet been identified. Taken together, HHT1 and HHT2
account for more than 80% of cases of HHT. Consequently,
most of the research in understanding this disease has focused
on investigating the roles of ENG and ACVRL1 and mouse
models carrying mutations in these genes form the focus of this
review.
HHT patients develop mucocutaneous lesions known as
telangiectases in the nose, mouth, and gastrointestinal (GI) tract,
as well as larger arteriovenous malformations (AVMs) in major
organs such as the lung, liver, and brain (Shovlin, 2010). The
telangiectases are comprised of fragile vessels that are susceptible
to rupture and hemorrhage, which means that HHT patients can
suffer recurrent anemia following frequent and severe bleeding
episodes. Bleeding telangiectases are also difficult to treat clin-
ically and many HHT patients suffer a lifetime of unpleasant
disease symptoms. In addition, large AVMs in major organs can
pose severe risks to life.
ENG and ACVRL1 proteins are expressed predominantly in
endothelial cells (ECs), but are also found in some other cell types.
For example, endoglin is expressed in myofibroblasts, mesenchy-
mal cells, and activated monocytes. Both ENG and ACVRL1 are
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FIGURE 1 | Role of endoglin and ACVRL1 in TGFβ family signaling. TGFβ
superfamily ligands bind to specific serine/threonine kinase receptors and
induce formation of a heteromeric receptor complex. In ECs, TGFβ1 ligand
activates ACVRL1/ALK5/TGFBR2 receptor complexes leading to
phosphorylation of SMAD1/5/8 which then interacts with SMAD4 protein and
moves to the nucleus to regulate transcription of target genes. BMP9 ligand
promotes Smad1/5/8-mediated signaling through ACVRL1-BMPR2 receptor
complexes. Endoglin promotes signaling through ACVRL1, potentially by
facilitating ligand binding to the signaling receptor complex. Under particular
environmental conditions (e.g., during inflammation) the extracellular domain
of endoglin is cleaved to form soluble endoglin (Sol-Eng), which may
sequester circulating BMP9/10 ligands and reduce receptor binding. Sol-Eng
has also been shown to inhibit binding of TGFβ to TGFBR2 (Venkatesha et al.,
2006) potentially by a sequestering mechanism (as shown).
expressed at the cell surface where they bind selected members of
the TGFβ family (Figure 1). ENG is a co-receptor that promotes
TGFβ family signaling through the signaling receptor ACVRL1
(Lebrin et al., 2004), and together they can form a protein
complex. In this way ENG and ACVRL1 are thought to work
together in the same signaling pathway, performing a similar role
in the cell, and consistent with the similar clinical phenotype of
HHT1 and HHT2. However, there are also some clinical differ-
ences between HHT1 and HHT2. HHT1 patients have a higher
incidence of pulmonary AVMS and cerebral AVMs, while HHT2
patients are more susceptible to GI bleeding and to liver AVMs
(Letteboer et al., 2006; Lesca et al., 2007; Shovlin, 2010; Komiyama
et al., 2014). It is not yet clear why these differences occur, but they
do point to overlapping, but non-identical functions for ENG and
ACVRL1. At present our understanding of disease mechanisms
is far from complete and therapies for patients remain limited.
Robust animal models of HHT are therefore important (i) to
increase our understanding of the disease mechanisms (thereby
underpinning the development of new treatments) and (ii) to
provide robust models for screening new therapies. In recent years
there have been considerable advances in the development of
mouse models of HHT and this review summarizes progress to
date.
MICE HOMOZYGOUS FOR NULL MUTATIONS IN Eng
OR Acvrl1
Mice lacking functional endoglin were generated independently
by gene targeting in three different laboratories (Bourdeau et al.,
1999; Li et al., 1999; Arthur et al., 2000). In all cases, total loss
of endoglin expression leads to cardiovascular defects and embry-
onic death by mid-gestation. Vasculogenesis does not appear to
be affected in these endoglin null mice, suggesting that endoglin
is not required for initial differentiation of ECs or for formation of
a primitive vascular plexus. The yolk sac of Eng−/− embryos has
enlarged fragile vessels, while the embryo proper shows cardiac
cushion defects and delayed maturation of major vessels, with
reduced vascular smooth muscle cell (vSMC) coverage. These
findings point to the importance of endoglin in angiogenesis
and for formation of the primitive cardiac cushions (which are
primordia of cardiac valves). Acvrl1 null (Acvrl1−/−) mice have
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a very similar phenotype with early embryonic lethality, yolk sac
angiogenesis defects, and delayed maturation of the embryonic
vessels (Oh et al., 2000). Once again vasculogenesis appears to
progress normally suggesting that Acvrl1 is required for angio-
genesis, but not for the initial formation of a primitive vascular
plexus. In a similar study, embryos lacking Acvrl1 develop large
shunts between arteries and veins, associated with downregu-
lation of genes involved in arterial vessel identity and reduced
vSMC coverage (Urness et al., 2000). This led to the initial idea
that AVMs in HHT form during development due to fusion of
arteries and veins because they have lost their normal molecular
identity.
Although the cause of the enlarged fragile vessels typical of
Eng−/− and Acvrl1−/− yolk sacs is unclear, these vessels represent
a useful (albeit primitive) model of HHT blood vessels. They were
used as a tissue model of HHT1 in an elegant study showing
that endoglin is required by ECs to produce locally active TGFβ1
protein (Carvalho et al., 2004). As this EC-derived TGFβ1 pro-
tein is critical for differentiation and maturation of the adjacent
vSMCs, the reduced TGFβ1 protein defect potentially explains
the reason for fragile vessels in HHT. In other words, in the
absence of endoglin, there may be insufficient molecular signal
(TGFβ1 protein) to permit the normal crosstalk from ECs to
the neighboring vSMCs to fully support vSMC maturation and
maintain a robust vascular wall (Carvalho et al., 2004). This
reduced vessel maturation phenotype is also seen, although much
less severely, in the endoglin heterozygous mice (Eng+/−) and is
discussed below.
HETEROZYGOUS (Eng+/− AND Acvrl1+/− ) MOUSE MODELS
OF HHT
Heterozygous (Eng+/− and Acvrl1+/−) mice are the closest genetic
models of HHT patients in terms of genotype. However, Eng+/−
and Acvrl1+/− mice have a very mild phenotype and HHT-
like features appear at low frequency (Bourdeau et al., 1999;
Srinivasan et al., 2003; Torsney et al., 2003). Although initially
disappointing for those of us working to develop a robust animal
model of HHT, this finding is important because it suggests that
additional triggers are required for development of HHT and if
these triggers can be minimized then HHT patients will have a
reduced risk of disease symptoms. The effect of environmental
triggers has mainly been tested in Eng+/− mice, but we will first
discuss the mild baseline defects in the Eng+/− and Acvrl1+/−mice
and then the potential environmental triggers for development of
HHT-like lesions.
BASELINE DEFECTS IN Acvrl1+/− AND Eng+/− MICE
Acvrl1+/− mice have dilated vessels and HHT-like vascular lesions
in liver, nailbed, intestine, or skin that develop between 7 and
20 months (Srinivasan et al., 2003). However, these lesions occur
at incomplete penetrance (approximately 40% Acvrl1+/− mice
have one or more lesions) and in an unpredictable manner.
Heterozygous Eng+/− mice also show a range of HHT-like vas-
cular lesions including nosebleeds, ear telangiectasias, and vessel
dilation that develop between 3 months and 2 years. HHT-like
lesions are more frequent in the 129/Ola genetic background
(affecting approximately 40–50% Eng+/− animals) suggesting that
genetic modifiers may play a role in susceptibility to HHT disease
(Bourdeau et al., 1999; Torsney et al., 2003). Importantly, these
mice also show reduced vascular smooth wall coverage of post-
capillary venules that is also more severe in the 129/Ola genetic
background (Torsney et al., 2003). As reduced vSMC coverage
of vessels is expected to increase susceptibility to hemorrhage, a
landmark study set out to test whether thalidomide, a vascular
maturation factor, would be beneficial for treating HHT (Lebrin
et al., 2010). Initially using the Eng+/− mouse model, thalidomide
treatment was shown to restore the reduced vSMC coverage of
vessels. More importantly, HHT patients treated with thalidomide
for 3 months also show reduced severity of epistaxis associated
with improved vSMC coverage of nasal mucocutaneous vessels
(Lebrin et al., 2010). These findings point to the value of using
thalidomide in the clinic for treating severe epistaxis in HHT.
However, there is little known about the long term benefits
of thalidomide treatment in HHT and thalidomide also carries
high health risks due to its major teratogenic and irreversible
neuropathic effects. Therefore, safer derivatives of thalidomide are
needed before this can be taken forward to clinical trials.
POTENTIAL TRIGGERS OF VASCULAR ABNORMALITIES IN Eng+/−
MICE: INFLAMMATION AND ANGIOGENESIS
An early study suggested that inflammation may be a trigger for
HHT, as bleeding lesions are more pronounced in the eyelids of
Eng+/− mice with blepharitis (Torsney et al., 2003). Moreover
there is evidence suggesting that Eng+/− mice are less able to
resolve inflammatory stimuli, which would mean a prolonga-
tion of this trigger (Jerkic et al., 2010; Shen et al., 2014). This
inflammatory environment also has an effect on the local level of
endoglin protein. The extracellular domain of endoglin is cleaved
from the cell surface by proteolysis (Hawinkels et al., 2010) and
the released soluble endoglin protein (Sol-Eng) may act as a “lig-
and sink” by binding circulating selected TGFβ family ligands to
disrupt the normal co-auxiliary receptor function of endothelial
endoglin. In fact, increased levels of Sol-Eng are observed in
patients with sporadic (non-familial) cerebral AVMs suggesting
excess Sol-Eng may disrupt local vessel organization (Chen et al.,
2009). Furthermore, endoglin is cleaved from the surface of ECs
following stimulation with the inflammatory protein TNFα (Li
et al., 2003). Therefore, reduced reservoirs of endoglin protein
on ECs (typical of HHT1 patients) combined with inflammatory
triggers would increase the risk of generating ECs with insufficient
or even no endoglin protein during the inflammatory period.
This transient so-called “endoglin protein null” phenotype would
increase the risk of vascular lesion development. Therefore anti-
inflammatory therapies such as anti-TNFα that would decrease
the risk of endoglin protein shedding may be beneficial in treating
HHT1. It is not yet clear whether an anti-inflammatory approach
would also be useful for HHT2 as further work needs to be
done on Acvrl1+/− mice to identify potential triggers of vascular
abnormalities.
As discussed above, heterozygous (Eng+/− and Acvrl1+/−)
mice develop relatively normal blood vessels suggesting there
are no major vascular defects during developmental angiogen-
esis. This also agrees with the fact that the majority of the
vasculature in HHT patients functions normally while vascular
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lesions are localized and sporadic. However, reduced angiogen-
esis in adult Eng+/− mice has been reported in pathological
conditions such as femoral artery ligation (Jerkic et al., 2006),
myocardial infarction (van Laake et al., 2006), or stroke (Shen
et al., 2014). Moreover, in a series of studies focusing on the
brain vasculature in Eng+/− and Acvrl1+/− mice, transient pro-
angiogenic stimulation generates abnormal vascular outcomes. In
the first study, stimulation of cerebral vasculature with adenoviral
particles expressing VEGF in Eng+/− mice leads to increased
vascular dysplasia but not overt AVMs (Xu et al., 2004). Like-
wise, intra-cerebral delivery of adeno-associated virus expressing
VEGF results in cerebrovascular dysplasia in both Eng+/− and
Acvrl1+/− mice, but with a higher degree of vascular dysplasia
and a higher capillary density in Eng+/− mice compared with
Acvrl1+/− mice (Hao et al., 2010). These studies show that angio-
genic stimulation is required for the development of vascular
dysplasia in heterozygous models. Taken together these studies
support the premise that normal levels of endoglin and Acvrl1 are
required for typical angiogenic responses and that angiogenesis
represents a likely trigger for the formation of abnormal vessels in
HHT. However, heterozygosity for Eng or Acvrl1 mutations, even
in combination with pro-angiogenic triggers, was not sufficient
to trigger AVM formation suggesting that a further event was
required.
Eng- INDUCIBLE KNOCKOUT (iKO) AND Acvrl1 -iKO
MICE—MODELS OF HHT1 AND HHT2
To evaluate whether losing the remaining functional Eng or
Acvrl1 allele in postnatal life leads to a better mouse model of
HHT pathology, genetic tools such as Cre-lox technology have
been used to deplete (or “knock out”) the target genes (Eng
or Acvrl1) at a time of choice (Figure 2). In contrast to mice
that are heterozygous for mutations in either Eng or Acvrl1,
which overall have only mild vascular defects, homozygous dele-
tions of Eng or Acvrl1 using cell type-specific or time-dependent
Cre drivers result in consistent and robust AVMs resembling
those seen in HHT patients. Importantly, however, these AVMs
are generally limited to sites where there is a pro-angiogenic
or inflammatory environment, as described in the following
sections.
PRO-ANGIOGENIC OR INFLAMMATORY STIMULI ARE REQUIRED
FOR THE DEVELOPMENT OF AVMs IN Eng OR Acvrl1 -DEFICIENT SKIN
AND BRAIN
Homozygous loss of the Acvrl1 gene in adult life is required
but is not sufficient to trigger AV shunts in cutaneous vessels.
An additional environmental insult is required; for example der-
mal wounding leads to AVMs at the wounded site in Acvrl1-
deficient mice (Park et al., 2009). These “wound-induced AVMs”
also occur in Eng-deficient mice (Choi et al., 2014; Garrido-
Martin et al., 2014). Furthermore, local application of molecular
stimulators of angiogenesis or inflammation such as VEGF or
LPS triggers the formation of skin AVMs, while VEGF neutral-
izing antibody is able to reduce wound-induced AVMs (Han
et al., 2014). These results suggest that two genetic hits (loss of
both Eng alleles, or loss of both Acvrl1 alleles) combined with
environmental pro-angiogenic triggers are necessary for AVM
development, the so-called “three event hypothesis” (Figure 3).
This three hit paradigm was also observed for brain AVMs in
a series of studies delivering local intra-cerebral injection of a
Cre expressing adenovirus into the basal ganglia of adult mice
carrying floxed Eng (Engfl/fl) or floxed Acvrl1 (Acvrl1fl/fl) alle-
les. This approach generated regional loss of the target Eng or
Acvrl1 gene, which alone had minimal effect on the vascula-
ture. However, when angiogenesis is triggered by local injection
of adeno-associated viral vectors expressing VEGF, abnormal
vessels with arteriovenous shunting develop that resemble the
human brain AVM phenotype (Walker et al., 2011; Choi et al.,
2012; Chen et al., 2013). Interestingly, more dysplastic vessels
are induced per copy of Eng deletion than per copy of Acvrl1
deletion (Choi et al., 2012), consistent with the observation
that HHT1 patients have a higher incidence of brain AVMs
than HHT2 patients (Letteboer et al., 2006; Komiyama et al.,
2014). All of these mouse studies (Park et al., 2009; Walker
et al., 2011; Choi et al., 2012, 2014; Chen et al., 2013; Garrido-
Martin et al., 2014; Han et al., 2014) support the idea that a
combination of events are needed for AVM formation; first loss
of Acvrl1 or Eng protein (either by a second genetic hit or a
proteolytic mechanism) followed by a pro-angiogenic or inflam-
matory trigger; for example, by exposure to VEGF or wounding
(Figure 3).
FIGURE 2 | Floxed mice used to generate models of HHT. The floxed
endoglin mouse (A) and the floxed Acvrl1 mouse (B) were generated for
conditional knockout studies using Cre-LoxP recombination (Allinson
et al., 2007; Park et al., 2008). The floxed endoglin mouse (A) was
designed with the position of loxP sites (arrowheads) to allow conditional
deletions of exons (boxed regions) 5 and 6 of the Endoglin gene, which
also leads to a frameshift mutation in exon 7 to generate a truncated
non-functional protein. Cre mediated recombination of the floxed Acvrl1
allele (B) leads to removal of exons 4–6 which includes the essential
transmembrane domain. To achieve cell-type specific knockdown of
endoglin or Acvrl1, these floxed mice were crossed with specific
Cre-lines (see Tables 1 and 2).
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FIGURE 3 | Three event hypothesis for AVM formation in HHT. Individual
endothelial cells in HHT patients may undergo local loss of endoglin or
ACVRL1 protein either due to shedding or somatic mutation. If vessels
containing these transient or permanent null cells are exposed to
pro-angiogenic triggers then the cells may undergo further proliferation and
contribute to vessel enlargement. We suggest that once blood flow increases
in this enlarged vessel there is a positive feedback loop leading to further
endothelial cell proliferation and vessel enlargement.
Table 1 | Summary of HHT phenotypes in conditional endoglin knockout mouse models with different Cre lines.
Cre line Targeted cell type
(Cre expression)
HHT phenotype Reference
Cdh5-Cre-ERT2 ECs (Cre activated
in neonate or adult).
Neonatal- retinal AVMs Adult -enlarged
subdermal veins adjacent to matrigel plugs
containing VEGF+FGF
Mahmoud et al. (2010)
R26-CreER All cell types AVMs -dependent on VEGF stimulation or
wounding
Choi et al. (2014), Garrido-Martin et al. (2014)
SM22α-Cre vSMCs and ECs Sporadic AVMs and micro-hemorrhage in
brain and spinal cord. 50% mortality by 6 wks
Choi et al. (2014)
LysM-Cre Macrophage No phenotype detected Choi et al. (2014)
Scl-CreER ECs Skin AVMs following wounding Garrido-Martin et al. (2014)
Myh11-CreER vSMCs No phenotype detected Garrido-Martin et al. (2014)
Note that Cre-ER is only activated following tamoxifen treatment, which is given in adult life unless otherwise stated.
ENDOTHELIAL-SPECIFIC LOSS OF Eng OR Acvrl1 PREDISPOSES
VASCULATURE TO AVM FORMATION
In order to determine which are the critical cell types where
Eng and Acvrl1 play their essential roles in vascular development
and maintenance, a range of different transgenic Cre lines have
been used to conditionally deplete Eng or Acvrl1 in different
cell types. Subsequently, vessel remodeling in response to a pro-
angiogenic or inflammatory stimulus can be evaluated in each
mouse line. Key findings from these in vivo studies are summa-
rized in Tables 1 and 2. It is clear that the key cell type is the
endothelial cell: loss of Acvrl1 or endoglin protein from vascular
endothelium is a prerequisite for AVM formation whereas loss of
these genes in other cell types (vSMCs, pericytes, or macrophage)
has no detectable effect on AVM formation. It is also important to
note that the pro-angiogenic signals vary in these different mouse
models: in some cases investigations have focused on normal
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Table 2 | Summary of HHT phenotypes in conditional Acvlr1 knockout mouse models with different Cre lines.
Cre line Targeted cell type
(Cre expression)
HHT phenotype Reference
R26-CreER All cell types GI and lung hemorrhage. Dermal AVMs dependent
on dermal wounding. 100% mortality
Park et al. (2009), Han et al. (2014)
L1-Cre Arterial ECs of brain, lung,
and GI tract (Cre active
from late embryogenesis)
AVMs and hemorrhage in brain, lung, and GI tract.
100% mortality
Park et al. (2009)
Cdh5-CreERT2 ECs (Cre activated in
neonate or adult).
Neonatal: retinal AVMs, lung hemorrhage, 100%
mortality Adult: cecal hemorrhage, 100% mortality
Tual-Chalot et al. (2014)
Scl-CreER ECs Skin AVMs following wounding Visceral AVMs in
absence of any additional external trigger 100%
mortality
Garrido-Martin et al. (2014)
Myh11-CreER vSMCs No phenotype detected Garrido-Martin et al. (2014)
Sm22α-Cre vSMCs and ECs Cerebral and spinal AVMs. High mortality Milton et al. (2012)
NG2-CreER Pericytes No phenotype detected Chen et al. (2014a)
Pdgfb-CreER ECs AVMs in brain following local VEGF stimulation; lung
hemorrhage and visceral AVMs. 100% mortality
Chen et al. (2014a)
Note that Cre-ER is only activated following tamoxifen treatment, which is given in adult life unless otherwise stated.
FIGURE 4 | Arteriovenous malformations in mouse neonatal retinas
following endothelial specific loss of Eng or Acvrl1 expression.
Endothelial cells of the neonatal retinal are stained with isolectin to reveal
normal two-dimensional architecture of the vascular plexus at postnatal day 7
(P7). Note the regular organization of arteries (a) and veins (v) with intervening
capillary networks (A), and at higher magnification (B). Arteries are readily
recognized by the capillary free zones around them (A,B). Following
endothelial specific depletion of endoglin (by tamoxifen treatment of Engfl/fl;
Cdh5-CreERT2 neonates), Eng-iKOe retinal vessels at P7 show delayed
progression of the vascular plexus toward the edge of the retina as well as
abnormal connections between arteries and veins to generate multiple AVMs
[red arrows in (C), and shown in higher power images in (D)]. Endothelial
specific loss of Acvrl1 leads to AVMs (red arrows in E,F), hyperbranching
(F, asterisks) and enlargement of veins. Panels (A,C) are reproduced from a
previous study where further details of the experimental approach can be
found (Mahmoud et al., 2010; Tual-Chalot et al., 2014).
developmental angiogenesis in early postnatal life, while in other
cases experiments have used wounding or inflammation as envi-
ronmental insults to trigger vascular remodeling in adult mice.
The effect of conditional knockdown of endoglin in ECs
was first examined in detail using the mouse neonatal retina
(Mahmoud et al., 2010). The mouse retina undergoes a well
characterized process of blood vessel development during the first
week of life. Retinal vessels arise from the center of the retina
close to the optic nerve by postnatal day 1 (P1), and develop
by angiogenesis (gradually growing outward from the optic disk
toward the periphery) to form a highly organized vascular plexus
that reaches the retinal periphery by P8 (Fruttiger, 2007). In this
way, neonatal retinal blood vessels form a characteristic alternat-
ing pattern of arteries and veins with an intervening capillary
network in a simple two-dimensional vascular plexus (Figure 4).
This means that any abnormal angiogenesis events can be readily
observed and characterized. In addition, using appropriate stain-
ing methods, individual ECs can be detected, permitting tracking
of fundamental EC properties such as cell proliferation, arterial,
and venous identity, cell-specific signaling as well as smooth
muscle cell coverage. Endoglin knockdown in ECs results in a
clear AVM phenotype in the neonatal retinal vasculature that is
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reminiscent of vascular malformations in HHT (Mahmoud et al.,
2010). Furthermore, the retinal vasculature of these inducible
endothelial specific endoglin knockout mice (Eng-iKOe) show
delayed angiogenesis, an increased level of EC proliferation and
enlarged veins (Figure 4). The arteriovenous connections have
a venous phenotype and become more muscularized over time
(Mahmoud et al., 2010), likely in response to increased blood
flow. This is similar to the venous muscularization phenotype
that was reported for dermal AVMs in HHT patients (Braverman
et al., 1990). Moreover, delayed progression of the vascular plexus,
is a very reproducible phenotype in the Eng-iKOe retinas. Here,
the delayed plexus is thicker than normal suggesting a defect in
intercalation of ECs and a failure of the vessels to migrate and
branch out correctly. No AVMs are observed when endoglin was
depleted in ECs of adult mice, suggesting that developmental
angiogenesis is an essential trigger for AVM formation, in line
with the “three event” hypothesis (Figure 3).
A similar model using endothelial specific depletion of Acvrl1
in early postnatal life (Acvrl1-iKOe) revealed a neonatal retinal
vessel phenotype that overlaps with that of Eng-iKOe neonates
(Tual-Chalot et al., 2014). The overlapping features are venous
enlargement, increased EC proliferation and AVMs (Figure 4).
However, Acvrl1-iKOe retinas show additional phenotypes that
include vascular hyperbranching and loss of arterial identity. The
vascular hyperbranching in the presence of reduced Acvrl1 signal-
ing is suggested to be due to defects in the cross talk that normally
occurs between Acvrl1 and Notch signaling pathways (Larrivee
et al., 2012). Reduced Acvrl1 levels leads to reduced Smad1/5/8
signaling in vivo (Tual-Chalot et al., 2014) and this may also
reduce Notch signaling, resulting in increased tip cell formation
and hyperbranching. In addition, Eng expression (at both RNA
and protein level) is markedly down-regulated in Acvrl1-depleted
ECs indicating endoglin expression to be downstream of Acvrl1
signaling in vivo (Tual-Chalot et al., 2014) and in agreement
with a previous study showing endothelial endoglin expression
is downstream of BMP9 signaling (Scharpfenecker et al., 2007),
likely through Acvrl1.
Conditional deletion of Acvrl1 in vSMCs and a subpopulation
of ECs using the SM22α-Cre transgene results in mice with
AVMs in the brain and/or spinal cord. This is associated with
paralysis or internal hemorrhages during the first 10–15 weeks
of life, and a high degree of mortality, although some mice
survive with multiple AVMs (Milton et al., 2012). As Cre is
expressed in both vSMCs and ECs in this line, then it is not
clear which is the responsible cell type. This was addressed in
a more recent study that also compared the development of
visceral and cutaneous AVMs in adult Eng- and Acvrl1-iKO mouse
models (Garrido-Martin et al., 2014). Eng or Acvrl1 were first
deleted from vascular ECs in adult life using Scl-CreER, then
angiogenesis/inflammation was stimulated using a skin wounding
model and this resulted (in both Eng- and Acvrl1-iKOe models)
in the formation of AVMs that were monitored in real time. In
the Acvrl1-iKOe mice the arteriovenous connections grew over
time, but the dermal vessels of Eng-iKOe mice exhibited a much
more dynamic AVM remodeling (Garrido-Martin et al., 2014).
The reason for these different vessel responses is not clear. It
may be due to technical issues (e.g., different levels of Eng and
Acvrl1 knockout) or reflect slightly different roles of endoglin
and Acvrl1 in vivo. Further work is required to discriminate
between these possibilities. It is also important to emphasize here
that Scl-CreER transgenic mice show minimal Cre recombinase
activities in bone marrow derived cells in adult mice (Gothert
et al., 2004; Garrido-Martin et al., 2014) suggesting that the AVMs
are due to loss of Eng or Acvrl1 in ECs. However, it remains to be
formally shown whether hematopoietic stem cells do significantly
contribute to HHT disease. This is important because transfer of
bone marrow from Eng+/− mice was sufficient to cause cerebral
vascular dysplasia following VEGF stimulation (Choi et al., 2013)
and hematopoietic stem/progenitor cells appear to play a key role
in vessel maturation (Goossens et al., 2011). The Cre lines used to
date have only shown that loss of endoglin in LysM expressing
macrophage is insufficient to cause cerebral AVMs following
angiogenic stimulation (Choi et al., 2014; Table 1). Importantly,
loss of endoglin or Acvrl1 in vSMCs had no detectable effect
on the blood vessels (Garrido-Martin et al., 2014) consistent
with work showing an EC requirement for these proteins during
developmental angiogenesis (Mahmoud et al., 2010; Tual-Chalot
et al., 2014). Independent studies also showed that endothelial
depletion of endoglin or Acvrl1 was a prerequisite for brain AVM
formation, whereas pericyte loss of Acvrl1 or macrophage specific
loss of endoglin did not contribute to the AVM phenotype (Chen
et al., 2014a; Choi et al., 2014). However, this does not rule out
a potential contributory role of macrophage in AVM formation
as monocytes and macrophage are associated with skin AVMs
in HHT (Braverman et al., 1990) and may, for example, provide
important pro-angiogenic signals. It is also of interest that one of
these studies observed a mixed contribution of Eng-null and wild-
type ECs in the induced brain vascular lesions (Choi et al., 2014),
supporting the idea that HHT patient AVMs may be mosaic for
affected and unaffected ECs.
Intriguingly, the GI tract appears to be an exception to the
three event “rule” shown in Figure 3, because endothelial loss of
endothelial Acvrl1 alone is sufficient for GI bleeding (Tual-Chalot
et al., 2014) and Acvrl1-iKO mice show AVMs in the absence of
any overt pro-angiogenic trigger (Park et al., 2009). This could
be a peculiar feature of the delicate GI vasculature which may
have a high requirement for Acvrl1 function, or because there are
subtle pro-angiogenic or inflammatory signals present (possibly
triggered by the gut flora or tissue macrophage), which have not
yet been formally evaluated in this model. In contrast, endothelial
depletion of endoglin does not lead to AVMs in the GI vasculature
(Garrido-Martin et al., 2014), and this phenotypic difference in
the Acvrl1-iKO and Eng-iKO mouse models is also consistent with
the increased frequency of bleeding GI lesions in HHT2 compared
with HHT1 patients (Letteboer et al., 2006; Lesca et al., 2007;
Komiyama et al., 2014).
MOUSE MODELS OF HHT INDICATE THAT AVMs IN HHT
PATIENTS WILL OCCUR FOLLOWING LOSS
OF HETEROZYGOSITY
As discussed above, data from these more recent mouse models of
HHT shows that homozygous loss of Eng or Acvrl1 gene function
is a prerequisite for AVM formation. This raises the question of
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how this might occur in HHT patients. One possibility is the
(local) occurrence of somatic mutations in the remaining normal
allele of ENG (for HHT1) or ACVRL1 (for HHT2) to generate
loss of heterozygosity (LOH). We propose that LOH due to a
somatic second hit will inevitably precipitate susceptibility to
disease pathology in HHT. This idea may also explain why clinical
symptoms increase with age in HHT patients, as somatic muta-
tions in ENG or ACVRL1 would accrue. In fact, it was proposed
some time ago that local LOH may be required to develop the
vascular lesions seen in HHT (Berg et al., 1997). In this way,
somatic mutations would increase the number of ECs that are
null for endoglin (in HHT1) or null for ACVRL1 (in HHT2)
and following exposure to angiogenic or inflammatory signals
these “null” ECs would be associated with vascular malformations
(Figure 3). To our knowledge only one study has so far addressed
this question in tissues from HHT1 patients (Bourdeau et al.,
2000). The results show no local loss of endoglin protein expres-
sion in ECs within one cerebral AVM or one pulmonary AVM and
it was therefore concluded that AVMs are unlikely to be due to loss
of the second endoglin allele (Bourdeau et al., 2000). However, it
is possible that those cells harboring the LOH mutation within
the AV shunts could represent a small subpopulation of cells,
in which case an immunohistochemical approach may not be
sufficiently sensitive to detect a mosaic LOH. Interestingly, studies
evaluating the pathogenesis of numerous related familial vascu-
lar malformations, including cerebral cavernous malformation,
venous malformation, and glomuvenous malformation all reveal
LOH mutations within a subset of cells comprising the vascular
lesions (Brouillard and Vikkula, 2007; Akers et al., 2009; Limaye
et al., 2009a,b). These findings reinforce the need for LOH to
be re-assessed in vascular lesions from HHT patients using the
advanced DNA sequencing techniques that are now available.
IMAGING AVM FORMATION IN REAL TIME
An important technological advance using spectral imaging of
the dorsal murine skin allows AVM formation to be visualized
in real time in a skinfold window chamber system (Park et al.,
2009; Garrido-Martin et al., 2014; Han et al., 2014). The spectral
imaging system detects the levels of hemoglobin saturation within
any vessel segments to distinguish arterial from venous blood
flow, and thus visual detection of AV shunting at the earliest stages
is possible. The process of wound-induced AVM formation in
the absence of Acvrl1 can be divided into three phases; initiation,
maturation, and maintenance (Han et al., 2014; Figure 5). In the
FIGURE 5 | Stages of AVM development in mouse skin AVMs
following loss of Acvrl1 combined with wounding. The novel
connections between nascent arteries and veins can be seen by
following hyperspectral imaging of the wound area in a dorsal
window chamber in real time. The color bar indicates the relative
oxygen saturation levels of the hemoglobin which allows tracking
of arterial (red) and venous (blue) blood flow. Four novel AV
shunts (AV1–4) appear over the course of 7 days following
wounding. Arterial blood flowing into venous branches through
AV shunts can be visualized. For instance, “blue” venous
branches (marked by a blue asterisk or star) in day 2 (A) turned to
“red” by connecting to adjacent arterial branches (marked by red
asterisk for AV1 and star for AV2) in day 3 (B), indicating
establishment of AV shunts. A portion of this data and further
methodological details can also be found in a previous publication
(Han et al., 2014).
Frontiers in Genetics | Genetic Disorders February 2015 | Volume 6 | Article 25 | 8
Tual-Chalot et al. Mouse models of HHT
initiation phase (2–4 days after wounding and Acvrl1-deletion),
active angiogenic reaction is evident and AV shunts are estab-
lished. In the maturation phase (4–6 days postwounding), blood
vessels connected to the AV shunts begin to remodel, leading
to dilatation of veins and arteries, and regression of capillaries
and small vessels, probably due to hemodynamic changes. In
the maintenance phase (7–9 days postwounding), further remod-
eling and regression of small vessels occurs but there are no
overall changes in the structure of AV shunts. The process of
wound-induced AVM formation in the absence of endothelial Eng
appears to be more dynamic with arteriovenous shunts forming
around day 6 after wounding and then regressing while new
shunts formed nearby (Garrido-Martin et al., 2014). Combina-
tions of brightfield and hyperspectral images and fluorescence
video recording in this system is an important tool to examine the
onset, progression, remodeling, and hemodynamic characters of
these AV shunts in real time to reveal more about the development
and progression of AVMs.
MAIN CONCLUSIONS FROM THE MOUSE STUDIES
The main phenotypes of the conditional knockout mouse models
examined to date (summarized in Tables 1 and 2) has led to
the recognition that the endothelial cell is the critical cell type in
HHT. Endothelial expression of Eng and Acvrl1 protects against
AVM formation and hemorrhage, whereas loss of Eng or Acvrl1
in vSMCs, pericytes or macrophage does not lead to HHT symp-
toms. Furthermore, loss of Eng or Acvrl1 in ECs does not have to
occur in all the ECs of an AVM and there may be mosaicism for
loss of the target allele. Also, time is required for the evolution of
an AVM in the mouse models: both dermal and retinal AVMs take
a few days to form and subsequently enlarge over time.
The mouse models have also led to the proposal that three
events (heterozygosity of Eng or Acvrl1 mutation, plus LOH,
plus a pro-angiogenic trigger) are necessary for AVM formation
(Figure 3). We have called this the three event hypothesis for AVM
formation. Loss of Eng or Acvrl1 in ECs is required but alone is
not sufficient for AVM formation (with the exception of the GI
tract AVMs in Acvrl1-iKO mice, discussed above). Heterozygosity
of ENG or ACVRL1 mutations represents the baseline situation in
HHT1 and HHT2, respectively. Somatic mutations can then lead
to total loss of either ENG or ACVRL1 gene function in individual
ECs or EC lineages. Alternatively, at least for ENG, there can
be local transient loss of ENG protein due to protein shedding
during inflammatory events. (We do not yet know whether Acvrl1
protein is also shed from ECs in inflamed tissues.) The third
event required for AVM formation is a pro-angiogenic trigger.
This may simply be the normal development process of forming
new blood vessels during embryological or postnatal growth.
Alternatively, angiogenesis may occur during pathological events,
e.g., inflammatory angiogenesis, a possibility that aligns with the
so called “response to injury paradigm” to explain why AVMs may
follow pathologies or tissue trauma.
STRENGTHS AND LIMITATIONS OF CURRENT MOUSE
MODELS OF HHT
As discussed above and summarized in Tables 1 and 2, a range
of different mouse models have been used to model the clinical
features of HHT. The phenotypic outcomes largely depend on
the Cre line being used and the stage of development or adult
life when Cre is active to target Eng or Acvrl1 genes. There are
also technical issues such as how reproducibly the Cre-ER is
expressed and activated; and how efficiently the target gene is
“knocked out” in each case. For example the SM22α-Cre line has
mosaic Cre activity in ECs during development, so AVMs occur
in unpredictable locations, making it challenging to use these
models for screening new therapies. In contrast, local wounding
of the skin of Acvrl1-iKO mice in adult life leads to the formation
of dermal AVMs in predictable sites and timescales that can be
imaged in real time and used to test treatment strategies. For
example, topical application of a VEGF-neutralizing antibody
shortly after wounding can prevent the formation of AVMs in
the skin of Acvrl1-iKO mice (Han et al., 2014). Alternatively,
if VEGF is neutralized following initial AVM formation then it
can block further progression of established AVMs or even cause
regression of early AVMs (Han et al., 2014). Similarly, anti-VEGF
treatment leads to attenuation of murine brain AVMs that form
following the combination of local angiogenic stimulation and
Acvrl1 depletion (Walker et al., 2012). These findings bode well
for current anti-VEGF therapies in clinical trial for HHT patients
(Kanellopoulou and Alexopoulou, 2013).
In terms of furthering our understanding of the events leading
to AVM formation, the neonatal mouse retinal model provides
a useful way to analyze the cellular and molecular changes that
occur during development of a well characterized vascular plexus,
while spectral imaging of adult mouse skin permits an overview of
vascular remodeling in real time. Ultimately, technical advances in
cell labeling and real time imaging will allow us to track individual
ECs during formation of AVMs in these mouse models. In fact, the
transparency of the zebrafish embryo already permits this type
of study. Loss of Acvrl1 function leads to dilated cranial vessels
that are characterized by increased EC numbers and stabilized
by increased blood flow (Roman et al., 2002; Corti et al., 2011),
suggesting that blood flow is a major factor in the maintenance
and progression of AVMs. This remains to be formally shown in
the mouse models of HHT.
A limitation of using mouse models is that it is not practical
to investigate the pathogenicity of all individual HHT muta-
tions, due to the cost and time required for detailed in vivo
studies. However, the advent of new technologies to manipu-
late the mouse genome (e.g., CRISPR) means that these types
of studies will become more and more efficient allowing the
routine generation of animal models with patient-specific muta-
tions. In the meantime, to meet this challenge, some patient
specific cell based screens are available for diagnostic testing
of patient specific mutations (Ricard et al., 2010; Mallet et al.,
2014).
HOW HAVE MOUSE MODELS OF HHT INFORMED CLINICAL
CARE ANDWHAT IS THEIR FUTURE POTENTIAL?
Evidence based medicine requires that clinical care is based on
well informed decisions founded on robust research data from
both clinical and basic science studies. The mouse models of
HHT analyzed to date suggest that prevention of inflammation
or angiogenesis would reduce the risk of AVM formation, while
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vascular stabilization agents would reduce the risk of hemorrhage.
In addition, our increased understanding of disease mechanisms,
including data from these mouse models, suggest that anti-
inflammatory agents such as anti-TNFα therapy may be benefi-
cial, at least for HHT1 patients, by reducing Eng protein shedding
and protecting the vasculature during infections.
Furthermore, the most robust and reproducible mouse models
of HHT are currently being used to develop therapies for preven-
tion and for disease treatment. The Acvrl-iKOe mouse provides a
useful model for preclinical screening of potential therapies for GI
bleeding, while Eng-iKOe and Acvrl1-iKOe mice provide valuable
screening tools for evaluating therapies to reduce (or even reverse)
AVM formation. Work showing the vascular stabilization role of
thalidomide in a mouse model of HHT1 (Lebrin et al., 2010)
underpins ongoing clinical trials to test whether thalidomide
can reduce the severity of epistaxis in HHT. Furthermore, the
extensive mouse model data revealing the critical role of angio-
genesis triggers for AVM formation (Park et al., 2009; Mahmoud
et al., 2010; Walker et al., 2011; Choi et al., 2012; Chen et al.,
2014b; Garrido-Martin et al., 2014; Tual-Chalot et al., 2014) and
the protective effect of anti-VEGF treatment (Han et al., 2014)
supports promising findings from anti-angiogenic therapy using
Bevacizumab in early clinical trials which appears to reduce the
frequency and intensity of epistaxis, GI bleeding episodes, and
liver AVMs, while topical administration reduces the frequency
and the severity of epistaxis (Kanellopoulou and Alexopoulou,
2013).
OUTSTANDING QUESTIONS AND FUTURE CHALLENGES
This review has focused on mouse models of HHT1 and HHT2.
However, there are approximately 15–20% of HHT patients with
no known ENG or ACVRL1 mutations and ultimately new mouse
models will be used to functionally investigate novel HHT genes
once they have been identified. In the meantime, mouse models
of HHT1 and HHT2 have reached an exciting stage and we
now are in a strong position to examine many outstanding
questions in the field; for example, whether AVMs always form
in the same manner and at what point in their development
they are reversible; whether EC proliferation always contributes
to enlargement of arteriovenous shunts and to what extent the
shunts are maintained, or exacerbated, by blood flow. Future
work will reveal whether these mouse models can reproduce both
the nidus-like “tangles” of vessels as well as the arteriovenous
fistulae seen in HHT patients; and may tell us why AVMs are
more common in lung and brain in HHT1 compared with HHT2
patients; or why the GI tract and liver are more susceptible
to vascular malformations in HHT2. These and many more
questions will be answered as the mouse models are further
refined and investigations continue. We are confident that the
next decade will bring important new insights into the under-
standing of HHT disease and we envisage a growing application
of these models in pre-clinical screens of new therapies for HHT
patients.
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